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Inflammation has long been associated with tumorigenesis.  Macrophages are cells of the 
innate immune system, whose density within tumors correlates with a worsening clinical 
prognosis in most types of tumors.  Macrophages have been demonstrated to contribute to 
the initiation, growth, invasion, and metastasis of tumors.  We hypothesized that 
macrophage density and phenotype differs between squamous cell carcinomas and basal 
cell carcinomas, two skin cancers with relatively aggressive and indolent clinical 
behaviors, respectively.  Through immunohistochemical analysis, we determined that 
squamous cell carcinomas have a 5-fold higher density of macrophages than basal cell 
carcinomas.  Tumor-associated macrophages exhibit two classic states of activation.  M1 
macrophages are inflammatory and are involved in clearance of microorganisms and 
tumor cells.  By contrast, M2 macrophages are involved in tissue remodeling, 
angiogenesis, and are tumor-promoting.  Using flow cytometric analysis of fresh clinical 
specimens, we determined that macrophages from squamous cell carcinomas express 
significantly higher levels of M1 (CD40, CD127) and M2 (arginase I) markers as well as 
higher levels of MMP-9, a pivotal enzyme in tumor matrix remodeling and tumor 
invasion, than macrophages from the basal cell carcinomas. To determine whether the 
Toll-like receptor (TLR) agonist imiquimod, an FDA-approved treatment for superficial 
basal cell carcinoma and actinic keratoses, alters the activation state of tumor-associated 
macrophages, we studied in vitro and in vivo effects of imiquimod on macrophages.  We 
determined that imiquimod activates primary macrophages from human squamous cell 
carcinoma to an M1, pro-inflammatory immunophenotype.  This phenotype was 
	  
	  
associated with enhanced macrophage-induced apoptosis of cultured epidermoid 
carcinoma cells and enhanced phagocytosis of fluorescently labeled tumor cells.  Our 
findings suggest that tumor-associated macrophages play a critical role in 
pathophysiology of two common human skin cancers.  Further, we provide a novel 
mechanism of action of imiquimod, which provides potential insights in the utilization of 
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Inflammation is recognized as being important for tumorigenesis and was recently 
proposed as the seventh hallmark of cancer (1-3). The inflammatory infiltrate in tumors 
most commonly consists predominantly of macrophages, T cells, neutrophils, natural 
killer (NK) cells – but includes other hematopoietic cells (4).  Among these cells, 
macrophages are the most numerous cells in this tumor infiltrate (5). Tumor-associated 
macrophages (TAMs) are closely involved in multiple stages of carcinogenesis: they 
contribute to initiation, growth, invasion, and metastasis of tumors through production of 
a diverse array of cytokines, growth factors, pro-angiogenic factors, and matrix 
metalloproteinases (6-8).  
The most common cancer in the United States is non-melanoma skin cancer with 
an estimated 1.3 million cases each year (9). The incidence of NMSC is increasing 
worldwide (10-12). It is essential to understand macrophage phenotypic characteristics in 
tumors of diverse clinical behavior to understand which factors correlate with tumor 
growth, invasion and metastasis. The two most common forms of NMSC are basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC) (13). BCC and SCC are ideal 
tumors to consider in study of TAMs in humans as they represent two common epidermal 
neoplasms that behave differently clinically. BCCs only grow and invade locally and do 
not metastasize (14, 15). In contrast, SCCs are more invasive and can metastasize in late 
stages (9). Sun exposure, specifically UV-B radiation, is considered to be one of the most 
important environmental factors involved in initiation of SCC (9). UV-B exposure 
directly leads to DNA and RNA damage through formation of pyrimidine dimers (13). A 




BCC, it has been shown recently that the number of TAMs infiltrating the tumor directly 
correlates with depth of tumor invasion and microvessel density (18). In cutaneous SCC, 
TAMs are shown to be a major source of VEGF-C, a critical lymphangiogenic factor 
(19). Therefore, study of in vivo TAMs in SCC and BCC represents a suitable strategy for 
further understanding of cutaneous carcinogenesis.  
TAMs classically exhibit two states of activation known as M1 and M2 states. 
Macrophages are polarized in response to Th1 cytokines, LPS and IFN-gamma, into an 
M1 state (2, 20, 21). On the other hand, in response to Th2 cytokines, IL-4 and IL-13, 
macrophages enter an M2 state (2, 21). M1 macrophages are inflammatory and produce a 
variety of pro-inflammatory factors such as IL-1β, TNF-α, and IL-6 (2, 21). In general, 
M1 macrophages are involved in clearance of microorganisms. M2 macrophages on the 
other hand are involved in type 2 inflammation, tissue remodeling, angiogenesis, and are 
believed to promote tumor growth (2, 22, 23). M2 macrophages produce high levels of 
Interleukin-10 (IL-10) and arginase I and express numerous scavenger receptors (2). The 
classical M1-M2 paradigm has been recently revealed to represent two ends of a 
spectrum that can also include heterogeneous states of activation.  It has been shown in 
multiple studies that macrophages can show mixed states of activation and there are 
multiple sub-populations of TAMs (24, 25). 
Imiquimod is a topically used imidazoquinoline drug approved by the Food and 
Drug Administration (FDA) for treatment of superficial BCCs, Actinic Keratoses, and 
warts (13). It is known to possess antiviral and anti-tumoral effects. Mechanistically, 
imiquimod is an immune response modifier and can also lead to direct tumor cell death, 




shown to be a specific agonist of TLR-7 in macrophages, a major arm of the innate 
immune system. Imiquimod and resiquimod (R848) activation of macrophages is 
MyD88-dependent (27, 28). We sought to characterize how TAMs are modulated by 
imiquimod both in vivo and in vitro. We utilized both imiquimod and resiquimod in our 
experiments. We hypothesized that imiquimod will act as a modulator of TAM 







STATEMENT OF PURPOSE & HYPOTHESIS 
 
The specific aims and hypotheses of this thesis project are as follows: 
1) Compare density of TAMs in human SCCs and BCCs:  
Hypothesis: Given that increasing macrophage density typically correlates with 
tumor aggressiveness, we hypothesize that there will be a higher density of TAMs 
in SCCs as compared to BCCs.  
2) Characterize in vivo M1-M2 immunophenotype of TAMs in SCC and BCC 
tumors using flow cytometry and determine whether tumor-derived soluble 
factor(s) are sufficient to reproduce this phenotype in vitro:  
Hypothesis: TAMs have differential activation in SCCs and BCCs, which may 
contribute to their distinct clinical behavior. Soluble factors derived from these 
tumors can induce human macrophages to assume an immunophenotype similar 
to the in vivo immunophenotype of TAMs in SCCs and BCCs. 
3) Determine whether imiquimod can modulate TAM immunophenotype in vivo 
and in vitro.  
Hypothesis: Imiquimod can polarize macrophages towards an M1, pro-
inflammatory state.  
4) Determine whether imiquimod-primed macrophages can induce apoptosis of 
tumor cells and enhance phagocytic capacity of macrophages for tumor cells 
Hypothesis: Imiquimod can activate macrophages to induce apoptosis of 
carcinoma cells. Furthermore, imiquimod can enhance phagocytosis of carcinoma 






All subjects participated voluntarily in this study after signing an informed consent. 
Human Investigation Committee approval was obtained prior to start of research project. 
Subjects were not exposed to any risks in this study as they were undergoing routine 
cutaneous surgery for the excision of skin cancer and agreed to donate the specimen for 
research. All experiments detailed in the subsequent sections were carried out by the 
author in Yale Departments of Dermatology and Immunobiology except for 
immunohistochemical staining of the SCC and BCC samples, which was performed by 
the Yale Dermatopathology Lab. Tumor histology was evaluated by board-certified 
dermatopathologists to ensure that tumors were either SCC or BCC prior to being 




Biopsy-proven BCCs (n=6) and SCCs (n=5) were confirmed by a dermatopathologist and 
utilized for immunohistochemical staining of TAMs. Tissue sections were stained with 
hematoxylin and eosin and CD68 antibody by the Yale Dermatopathology Lab. CD68+ 
macrophages were visualized at 40X magnification with OTIPHON Nikon microscope. 






II) Mechanical and enzymatic digestion of cutaneous tumors into single cell 
suspensions:  
Biopsy-proven cutaneous SCC and BCC extirpated by Mohs micrographic surgery were 
used after obtaining informed consent. The debulked tumor specimens were transported 
on ice. The tumors were weighed, and the length and width were measured to nearest 
millimeter. Next, the tumor was minced using surgical scissors into small pieces, all less 
than 2 mm in length. The digestion buffer consisting of Liberase TM at final 
concentration of 26 Wünsch/mL and DNase in PBS with calcium and magnesium was 
prepared. The specimen was then transferred to 10-20 mL of digestion buffer depending 
on tumor weight in a 50 mL conical tube. The digestion was carried out in a shaking 
incubator at 37 ºC for 90 minutes. After the end of the incubation period, 0.1 M 
Ethylenediaminetetraacetic acid (EDTA) was added at dilution of 1:50 and the digest was 
placed on ice for 5 minutes to stop the enzymatic reaction. In order to acquire a single 
cell suspension, the tumor digest was passed through a custom metal sieve designed to 
remove larger clumps of undigested matter. Next, the filtered liquid was passed through a 
70 µm cell strainer. This resulted in a homogenous cell suspension that was subsequently 
centrifuged at 1300 rpm for 5 min at 4 ºC. After centrifugation, the pellet was re-
suspended in ACK lysis buffer to lyse erythrocytes. The reaction was stopped with FACS 
buffer (0.5 % fetal bovine serum in PBS), and after centrifugation the final purified cell 
suspension was suspended in FACS buffer. Using trypan blue staining cell viability was 
assessed and cell count was approximated.  
 




The final tumor digests were plated in a 96-well plate at 1-2 million cells / well consisting 
of an unstained condition, and three separate panels designed to determine M1 and M2 
activation states in tumor associated macrophages. Prior to staining macrophages, Fc-
block was carried out by adding 50 µL of 1:200 diluted human Fc-Block solution 
(eBioscience) and the sample was incubated for 20 minutes on ice, in the dark. The 
sample was then washed with FACS buffer. The samples were then stained by adding 50 
uL of surface antibodies CD127-PerCP-Cy5.5, CD40-PerCP-Cy5.5, CD45-APC, and 
CD163-APC at recommended dilutions (eBioscience, Biolegend). The samples were 
incubated for 15 minutes in dark on ice. 150 uL of FACS buffer was added to each 
sample, followed by centrifugation at 1300 rpm for 5 minutes, and removal of 
supernatant. The wash was repeated a second time.  
Utilizing the standard protocol for intracellular staining from BD Biosciences, the 
samples were processed. The intracellular stains CD68-PE (2.5 uL per million cells), 
arginase I-CFS (10 µL per million cells, R&D systems) and MMP-9 CFS (10 µL per 
million cells, R&D Systems) were added to each sample in a final volume of 50 µL per 
well. The intracellular staining was carried out per manufacturer’s instructions (BD 
biosciences). All FACS analysis was carried out either immediately or within 12 hours 
with sample stored in dark and at 4 ºC. Single color controls were prepared utilizing BD 
Compensation beads (positive and negative beads) and the same antibodies used at 
identical dilutions per manufacturer’s instructions. All antibodies had Fc-gamma chains 
that are appropriate for use with the Comp Beads. FACS analysis was carried out on BD 
FACS Calibur. The PMT voltages were adjusted using the unstained sample containing 




replacing the staining steps with buffers. After setting appropriate voltages and gating on 
live cells based on Forward Scatter (FSC) and Side Scatter (SSC), the compensation was 
carried out with Comp Beads. Next, samples were analyzed with the BD FACS Calibur 
flow cytometer. To achieve statistical significance, 100,000-1 million events were 
collected for each sample. The acquired data was analyzed using FlowJo.  The 
preparation techniques, staining procedures, and antibody dilutions, and data analyses 
were identical for both BCCs and SCCs allowing direct comparison of FACS data. 
 
IV) Stimulation of THP-1 cells (human monocytic cell line) with tumor-conditioned 
media  
Tumor-conditioned media was prepared by manual mincing of SCC and BCC specimens 
with surgical scissors and re-suspending in complete RPMI media. The tumor-media 
suspension was incubated at 37 ºC in a humidified tissue culture (TC) incubator. The 
tumor supernatant was then carefully aspirated, centrifuged, and sterile filtered with 0.45 
µm syringe filter. The tumor-conditioned media were stored at -80°C for future 
experiments. For in vitro, stimulation of THP-1 cells (human monocytic cell line), 1 
million THP-1 cells were plated in 1 mL of tumor-conditioned media in sterile six-well 
tissue culture plates and incubated for 48 hours. The THP-1 cells were then utilized for 
flow cytometric immunophenotyping as previously described.  
 
V) Co-culture of human SCC, peri-tumoral skin with THP-1 cells 
For co-culture assay, fresh Mohs debulked SCC specimens and peri-tumoral normal skin 




complete media in the Transwell cell culture insert (1 µm) immediately after surgery. 1 
million THP-1 cells were plated in 1 mL of complete RPMI in six-well plates. The co-
culture assay was carried out for 48 hours and 72 hours in 37°C humidified TC incubator. 
A negative control with no co-culture was also included. At the end of incubation time, 
the upper insert was removed, and THP-1 cells were washed and utilized for flow 
cytometric immunophenotyping as described previously. 
 
VI) In vitro study of imiquimod’s effect on THP-1 cells 
THP-1 cells were plated in RMPI complete at density of 1 million/mL in sterile six-well 
or twelve-well tissue culture plates. The control conditions included negative control 
(plain RPMI complete), positive control (LPS 100 ng/mL, human IFN-gamma 20 ng/mL 
in RPMI complete. For in vitro study of mechanism of imiquimod, THP-1 cells were 
incubated in multi-well plates as follows:  1) Negative control. 2) Positive control 3) 50 
µg/mL imiquimod (Invivogen) 4) 10 µg/mL resiquimod (Invivogen). THP-1 cells were 
incubated for 48 hours in 37°C humidified TC incubator (5 % CO2). After 48 hours, cells 
were harvested with cold PBS and processed for flow cytometry. Briefly, cells were Fc-
blocked and stained with CD40, CD127, arginase I, MMP-9, CD45, and CD68 as 
described previously, and analyzed with BD FACS Calibur. Data was analyzed with 
FlowJo: Live cells were gated upon based on FSC and SSC. CD68+CD45+ THP-1 cells 
were next selected and histograms created for all the markers mentioned. For 
investigation of imiquimod's effects on TAMs, THP-1 cells were plated in sterile 12-well 
tissue culture plates with the following conditions included: BCC-conditioned media with 




50 µg/mL, and RPMI complete serving as negative control. After 48 hours of incubation 
in humidified 37°C TC incubator, THP-1 cells were harvested, washed, and prepared for 
FACS immunophenotype of M1, M2 and MMP-9 as previously described.  
 
VII) In vivo immunophenotype of TAMs imiquimod-treated patient 
For in vivo experiments, we obtained a fresh SCC debulk specimen in a patient treated 
with 2.5 % imiquimod for two weeks prior to surgery. A comparable SCC in a patient not 
treated with imiquimod was analyzed on the same day. We used the optimized enzymatic 
dissociation protocol, previously described, to create single cell suspensions. Next, the 
cell suspension was prepared for FACS immunophenotype and processed for both 
imiquimod treated SCC and control SCC. 
 
VIII) Apoptosis assay for evaluation of imiquimod-primed macrophages effect on 
A431 carcinoma cells 
THP-1 cells were stimulated with 50 µg/mL imiquimod in RPMI complete media. THP-1 
cells in RPMI complete media were used as negative controls. THP-1 cells were 
incubated for 48 hours in humidified TC incubator at 37°C. At the end of incubation, the 
THP-1 cells’ suspension was centrifuged at 1300 RPM for 5 min, and the supernatant 
was aspirated. Next, the pellet was re-suspended in 20 mL of cold PBS. The suspension 
was re-centrifuged and all of the supernatant was carefully aspirated. The final THP-1 
cell pellet was re-suspended in DMEM complete and placed on ice. A431 epidermoid 
carcinoma cells were plated in sterile non-tissue culture six-well plate at density of 1 




top of each well using sterile forceps. 1 million THP-1 cells from control and imiquimod 
pre-treated group were added to Transwell cell culture inserts in the six-well plate. The 
THP1-A431 co-culture plate was then incubated in a humidified TC incubator at 37 ºC 
for 72 hours. At the end of incubation, the upper cell culture insert containing THP-1 
cells was carefully removed. A431 epidermoid carcinoma cells were gently trypsinized 
off the wells and re-suspended in EMEM complete. Annexin V FITC apoptosis kit from 
eBioscience was used for the measurement of rate of apoptosis per manufacturer’s 
instructions. The tumor cells were first washed with cold PBS and then binding buffer.  
The samples were re-suspended in 200 µL of binding buffer. Five µL of Annexin V FITC 
was added to each well and mixed. The samples were then incubated for 10 minutes in 
dark. After completion of staining, the samples were washed with 200 µL of binding 
buffer. The samples were re-suspended in 200 µL of binding buffer and 5 µL of 
propidium iodide staining solution (eBioscience) was added. The samples were analyzed 
using FACS BD Calibur and compensations were carried out using unstained and BD 
compensation beads. Annexin V staining was calculated using the FITC channel and 
propidium iodide was measured in PerCP channel. Data was analyzed using FlowJo and 
Prism. Rate of early apoptosis was calculated as percentage of FITC positive cells. Rate 
of late apoptosis was calculated as percentage of FITC/PerCP double positive cells, 
which stained for both Annexin V-FITC and propidium iodide.  
 





THP-1 cells were stimulated using imiquimod 50 µg/mL in RPMI complete and 
control RPMI complete as previously described for 48 hours in humidified 37 ºC TC 
incubator. After end of incubation, the samples were centrifuged and the supernatants 
were aspirated. Twenty mL of cold PBS was used to wash the THP-1 cells. After 
centrifugation, all of the supernatant was carefully aspirated. The THP-1 cells were kept 
on ice. A431 epidermoid carcinoma cells were then labeled with PE fluorescent dye using 
PKH26 Red Fluorescent Cell Linker per manufacturer’s instructions (Sigma Aldrich). 
Briefly, A431 cells were first washed with serum-free media, and then re-suspended in 1 
mL of Diluent C. PKH26 dye solution was prepared in 1 mL of Diluent C by adding 4 uL 
of PKH26 dye. The prepared dye solution was rapidly added to the cell suspension and 
mixed thoroughly through pipetting up and down. The sample was then incubated for 2 
minutes and serum was added to stop the reaction. The sample was then centrifuged at 
400g for 10 minutes. The supernatant was aspirated and cells were suspended in 10 mL 
of complete media and transferred to a new tube. The cells were washed an additional 
two times with complete media prior to being used in experiments.  
PE-labeled tumor cells were then used for the purpose of phagocytosis 
experiments. One million THP-1 control cells were mixed with 6 million PE-labeled 
epidermoid carcinoma cells in a 50 mL conical tube, which served as the control group. 
One million THP-1 cells pre-treated with imiquimod were mixed with 6 million PE-
labeled epidermoid carcinoma cells, serving as the imiquimod group. Another condition 
included only THP-1 control cells without PE-labeled tumor cells to serve as cell-free 
control. The samples were then incubated in a shaking TC incubator for 60 minutes at 




cytometry as previously described using CD45-APC stain. Briefly, the samples were re-
suspended in FACS buffer and were Fc-Blocked using human Fc Block (eBioscience). 
Next, the samples were washed once with FACS buffer. CD45 APC was utilized to stain 
the samples (5 uL per 1 million cells) for 15 minutes in dark on ice. Next, the samples 
were washed with 200 uL of FACS buffer two times. The samples were analyzed on 
FACS Calibur. Rate of phagocytosis was determined by first gating on THP-1 cells using 
CD45-APC. After gating on macrophages, the percentage of PE-positive macrophages 
was used as marker of phagocytosis.  
 
X) Statistical analysis 
FACS data were analyzed with FlowJo. All statistical tests were performed with Prism 






The characteristics of subjects in this study for Immunophenotyping of TAMs in NMSCs, 
in vitro experiments, and imiquimod mechanistic experiments are shown in Table A.  
Age, gender, diagnosis, duration of lesion, and history of recurrent skin cancer for each 
patient are listed. Histopathologic diagnosis and features, tumor dimensions (mm), and 
anatomic locations are also shown (Table A).  
 
Human cutaneous SCCs have significantly higher density of TAMs compared to 
BCCs. 
In order to determine the density of TAMs in human cutaneous SCC, we stained H&E 
slides of biopsy-proven SCCs and BCCs with CD68 and quantified number of TAMs per 
high-power field (HPF). Analysis of SCCs (n=5) and BCCs (n=6) revealed that there is 
significantly higher density of TAMs in SCC compared to BCC (Figure 1b, p value < 
0.0001, unpaired two-tailed student t test). Representative histology of SCC and BCC are 
shown in Figure 1a demonstrating the distinctly different density of CD68+ TAMs in 
these two common forms of NMSC. 
 
Development of a method to analyze TAMs from primary SCC and BCC tumors 
Utilizing a combination of manual mechanical dissociation and enzymatic digestion with 
Liberase (Roche), we obtained a viable suspension from human SCCs and BCCs from 
multiple patients. All preparation was performed on the day of the Mohs micrographic 
surgery on patients with biopsy-proven cutaneous carcinomas. To our knowledge this 
represents the first successful FACS analysis of tumor associated macrophages in human 







cutaneous SCCs and BCCs. After optimization of the digestion process, we were able to 
obtain 5-30 million total cells from each tumor depending on weight. After the digestion 
process, cells were counted and trypan blue staining demonstrated that the cellular digest 
consisted of viable cells. The human tumor digest was then prepared for flow cytometric 
analysis of macrophages with multiple M1, M2, and TAM markers immediately after 
digestion. All FACS staining was performed on freshly digested specimens. Our 
immunophenotype panels were designed to characterize TAMs for their M1 and M2 
polarization states. CD127 (IL-7 receptor) and CD40 (co-stimulatory receptor) were used 
as M1 markers (2, 24, 29, 30).  Arginase I (2, 24) was used as an M2 marker. The 
advantage of FACS in comparison with immunohistochemistry is that multiple markers 
can be studied simultaneously and in a way to recognize multiple sub-populations. Given 
the recently recognized heterogeneity of TAM expression profile, FACS is an ideal 
method to detect distinct sub-populations of TAMs and also detect simultaneous M1 and 
M2 activation. 
By FACS analysis, we gated on a clear CD68+ CD45+ TAM population from 
both SCCs and BCCs. CD45 was utilized in addition to the classic macrophage maker 
(CD68) to ensure that only leukocytes were included in the analysis and tumor cells are 
excluded.  First, we selected for live cells by gating on FSC and SSC. The plot of CD68-
PE versus CD45-APC demonstrates a clear double positive population that represents 
TAMs in human BCC and SCC (Figure 2a).  In addition to CD68, we also used CD163, 
as another marker of TAMs in the skin. Percentage of C68+CD45+ TAMs in the tumor 
digest was not significantly different between SCCs and BCCs (mean 2.7 % in SCC 




immunohistochemistry and may represent a limitation of isolating individual living cells 
from tissue. 
 
TAMs from SCCs and BCCs have different degrees of polarization. 
Based on our analysis of published microarrays of NMSC, human cutaneous 
SCCs and BCCs have distinct microarray gene profiles of CD68, MMP-9 and arginase I 
(Figure 3). We analyzed published whole tumor microarrays of human SCCs (n=13) and 
BCCs (n=11) and Normal skin (n=4) to investigate expression profiles of CD68, arginase 
I, MMP-9 (31). Mean values of microarray signals for MMP-9, CD68, arginase I and 
SEM were calculated. Percentage present (%) was defined as percentage of all samples 
with significant p-values indicating that the gene is present in microarray profile of the 
tumor. In these expression arrays, CD68 was more highly expressed in SCC compared to 
BCC, and both skin cancers had higher CD68 expression than normal skin (Figure 3). 
MMP-9 shows stronger expression in SCC as compared to BCC and normal skin (Figure 
3). In addition, arginase I (probe 1) was present in significantly higher percentage of SCC 
tumors as compared to BCC (Figure 3). In a similar fashion, arginase I (probe 2) was 
present in 36% of SCC tumors yet completely absent from BCC and normal skin (Figure 
3). The results of whole tumor microarray analysis showed that CD68 (macrophage 
marker), arginase I (M2), and MMP-9 (TAM marker) had higher expression levels in 
SCC as compared to BCC and normal skin control. The results of this whole tumor 
microarray analysis suggested differential activation of TAMs in SCC versus BCC.  
To address this question using FACS analysis, SCCs (n=7) and BCCs (n=7) were 
processed for flow cytometric immunophenotyping of TAMs using an optimized method 







of enzymatic dissociation (Figure 2). We compared levels of arginase I and MMP-9 in 
TAMs in SCC (CD68+CD45+) in comparison with other leukocytes (CD68-CD45+) 
(Figure 2a-b). We observed significantly higher levels of both arginase I and MMP9 in 
TAMs as compared to other WBCs (Figure 2b). In addition, TAMs had higher levels of 
both arginase I and MMP-9 as compared to tumor cells (CD68-CD45-, data not 
displayed). 
 Immunophentyping of TAMs in human NMSCs demonstrated that TAMs in 
cutaneous SCC had significantly higher levels of MMP-9 compared to cutaneous BCC. 
This was demonstrated by a reproducible shift in histograms of MMP9-CFS observed in 
BCC and SCC (Figure 2c). In addition, intracellular human arginase I intracellular 
staining revealed that TAMs in SCC expressed higher levels of arginase I compared to 
TAMs in BCC (Figure 2c).  This demonstrated that macrophages in SCC are M2 
activated whereas macrophages in BCC have minimal M2 activation. In terms of 
expression of M1 markers CD127 and CD40, macrophages showed higher levels of both 
markers in as compared to BCC (Figure 2c-d). This trend was reproducible in multiple 
tumors from different patients as shown by overlaid representative histograms of CD40-
PerCP and CD127-PerCP in SCC (red) and BCC (blue) (Figure 2c-d). Similar results was 
seen in CD68+CD163+ as shown by significant shifts in histograms of arginase I (M2), 
MMP9 (TAM), CD40 (M1), and CD127 (M1) (Figure 2d).  
 
Sub-population analysis of SCC and BCC TAMs demonstrates the varied nature of 




The multi-color nature of flow cytometry allowed us to utilize the data for sub-
population analysis. In order to enhance analysis of data, M1 versus M2 graphs were 
created to help us delineate M1 and M2 activation of TAMs in SCC versus BCC.  CD127 
versus arginase I graphs demonstrated the following reproducible pattern as shown in 
tumors from different patients: TAMs from SCC are both M1 (CD127) and M2 (arginase 
I) activated. By comparison, TAMs from BCC mainly show a state of quiescence and 
demonstrate lower M1 and M2 activation (Figure 4). In BCC, a quadrant plot was used to 
analyze distribution of macrophage polarization. Macrophages are in a baseline state, 
meaning neither M1 nor M2 activated (78.7 %), only M1 activated (7.07 %), only M2 
activated (5.82 %), or express both M1 and M2 markers simultaneously (8.37 %) (Figure 
4). In order to compare this polarization pattern, we carried out a similar analysis in two 
SCCs. In a smaller-sized SCC, there are four distinct populations that can be appreciated 
in the FACS plot: baseline state (7.85 %), M1 only (42.8 %), M2 only (5.49 %), both M1 
and M2 activation (23.6 %). In a larger SCC, we delineated two populations: the majority 
of macrophages are M1 and M2 activated (94.1 %) and the rest are in a baseline state 
(4.02 %).  This type of sub-population analysis demonstrates that TAMs are not in one 
particular polarization program but rather can express M1 and M2 markers either 
individually or simultaneously (Figure 4). 
 
 





Immunophenotype of tumor-associated macrophages in cutaneous SCC was 
determined using flow cytometry and compared directly to tissue resident macrophages 
in peri-tumoral normal skin from the same subject. Biopsy-confirmed SCCs (n=3) from 
Mohs debulked tumor specimens and peri-tumoral normal skin (n=3) from the same 
patient were obtained. Both specimens were digested enzymatically and processed in an 
identical fashion for flow cytometric immunophenotype as previously described.  The 
experiment was performed a total of three times together with corresponding peri-tumoral 
normal skin. The results of this experiment show that TAMs in human SCCs are M1 
polarized as demonstrated by an increase in CD127 and CD40 levels as compared to peri-
tumoral normal skin (Figure 5). In addition, TAMs are also M2 polarized (increased 
arginase I) and produce increased levels of MMP-9 as compared to tissue resident 
macrophages in normal skin (Figure 5). 
 
Co-culture of human SCCs with naive THP-1 macrophages reproduces TAM 
polarization in vitro 
We designed an in vitro co-culture assay with human SCC and THP-1 cells to 
investigate whether a paracrine, non-contact-dependent communication between TAMs 
and SCC cells can account for our in vivo observation of heterogeneous M1 and M2 
polarization. Biopsy-confirmed cutaneous SCC from Mohs debulked tumors was 
mechanically dissociated with sterile surgical scissors and suspended in RPMI with 10 % 
FCS in a 1 um Transwell cell culture insert. In the lower chamber, THP-1 macrophages 
were plated at 1 million cells/mL. After 48 hours and 72 hours of co-culture, the upper 




MMP-9 expression.  For a control, we used peri-tumoral normal skin from the same 
patient, which was surgically removed from an adjacent anatomical location at the same 
time and co-cultured the dissociated skin with THP-1 macrophages. As a second negative 
control, THP-1 macrophages were grown fresh RPMI, without any other cells plated in 
co-culture. To analyze the state of polarization by FACS, we first gated live cells, 
followed by gating CD68+CD45+ cells, which represented the majority of THP-1 
macrophages.  THP-1s were polarized to heterogeneous M1 and M2 activation through 
paracrine interaction with human SCC tumor suspension (Figure 6). THP-1s displayed 
characteristics of M1 and M2 activation as demonstrated by significant shifts in arginase 
I, CD127 and CD40 compared to peri-tumoral normal skin and non-stimulated THP-1, 
which closely correlates with our in vivo findings of immunophenotype of TAMs in 
human SCCs. In addition, MMP-9 production is significantly increased through paracrine 
signaling of SCC cells co-cultured with THP-1s as compared to peri-tumoral normal skin 
co-culture (Figure 6).  Similar results are observed after 48 hours and 72 hours of 
incubation with SCCs from different patients. 
 
Soluble factor(s) in tumor-conditioned media from SCC and BCC differentially 
polarize human macrophages to a TAM phenotype 
Conditioned media was prepared from dissociated SCCs (n=3) and BCCs (n=3) in 
vitro. Biopsy-confirmed Mohs debulked tumor specimens were dissociated in a sterile 
environment and placed in RPMI-complete for 24 hours. The tumor supernatant was 
carefully aspirated and sterile filtered. THP-1 cells were incubated in the presence of 




in a humidified TC incubator at 37 ºC. Human macrophages demonstrate differential 
activation as a result of incubation in SCC- and BCC-conditioned media (Figure 7). THP-
1 cells incubated in SCC-conditioned media showed significant M1 and M2 polarization 
compared to either BCC or THP-1 cells control as demonstrated by significant shifts in 
histograms of CD40 (M1), CD127 (M1), and arginase I (M2) (Figure 7). In addition, 
MMP-9 production by THP-1 cells was strongly induced by SCC-conditioned compared 
to BCC-conditioned media (Figure 7). The results conform to findings from co-culture of 
THP-1 cells and SCC, and in vivo phenotype of TAMs in SCCs versus BCCs.  Soluble 
factor(s) present in tumor-conditioned media are sufficient to polarize THP-1 cells in 
vitro towards the respective TAM phenotype we observed in vivo in SCCs and BCCs. 
 
Imiquimod induces M1 activation of THP-1 cells in vitro as demonstrated by flow 
cytometry 
To determine, whether TLR-7/8-agonists were sufficient to polarize our THP-1 
monocytic cell line to an M1 state, we carried out in vitro experiments with both 
imiquimod and resiquimod, an investigational analogue of imiquimod.  THP-1 cells were 
plated in the control media or in media containing 50 µg/mL imiquimod or 10 µg/mL 
resiquimod.  Positive controls of the TLR-4 agonist LPS (100 ng/mL) and IFN-gamma 
(20 ng/mL) were included. After 48 hours, THP-1 cells were analyzed by flow cytometry 
for expression of M1 markers (CD40 and CD127). In analysis of results, live cells were 
gated on based on FSC and SSC. CD68+CD45+ cells were then selected and histograms 
of M1 markers were produced. Interestingly, imiquimod induced significant M1 




macrophages compared to negative control (Figure 8).  The positive control with LPS and 
IFN-gamma induced the expected shift in M1 markers (Figure 8). Resiquimod (TLR-7/8 
agonist) also induced M1 markers (Figure 8). Together, the results of these series of 
experiments demonstrate a possible immunologic mechanism for imiquimod, which 
involves amplification of M1 polarization state of macrophages.  
 
Imiquimod treatment leads to M1 polarization of TAMs in SCC in vivo  
We obtained a fresh SCC specimen from a patient treated for 2 weeks with topical 
2.5 % imiquimod treatment to scalp tumor. A comparable SCC was utilized as control. 
Both tumors were processed in parallel for flow cytometric analysis. In vivo 
immunophenotype of CD68+CD45+ macrophages was determined with FACS. In 
agreement with in vitro experiments, imiquimod treatment polarized TAMs to an M1 
activation state (Figure 9). We observed significant induction of CD40 by imiquimod as 
shown in Figure 9, with a majority of macrophages M1 polarized (94.5 %) in contrast to 
control SCC TAMs that were 45.8 % M1 polarized. Coordinately, there was also a 
positive shift in another M1 marker, CD127 (Figure 9).  Interestingly, imiquimod 
treatment leads to down-regulation of the tumor promoting metalloproteinase, MMP-9 by 
TAMs (Figure 9). Arginase I levels did not show an observable shift in this case (Figure 
9).  In summary, imiquimod treatment leads to M1 activation of TAMs and down-
regulation of MMP-9.  
 





We attempted to investigate whether imiquimod plays an immunomodulatory role 
for TAMs in the tumor microenvironment. To answer this question, we devised an 
experiment that models the tumor microenvironment. Briefly, THP-1 cells were plated in 
tumor-conditioned media from either SCC or BCC. The conditioned media was prepared 
from fresh Mohs debulked tumor specimens that were mechanically dissociated and 
placed in RPMI-complete for 24 hours, followed by sterile filtration with 0.45 µm filter 
and freezing at -80 ºC. THP-1 cells were plated in either BCC- or SCC-conditioned 
media in the presence or absence of 50 µg/mL imiquimod. After 48 hours of incubation, 
THP-1 cells were analyzed by flow cytometry for M1 (CD127), M2 (arginase I) and 
MMP-9. THP-1 cells stimulated by SCC supernatant alone were M1 and M2 activated as 
seen by upregulation of MMP-9, arginase I, CD127, and CD40. Stimulation by BCC 
supernatant alone also causes M1 and M2 activation though to a lesser degree. The levels 
of M1 and M2 markers, in contrast, are significantly modulated by presence of 
imiquimod in tumor supernatants. The results of this experiment indicate that imiquimod 
plays an immunomodulatory role by up-regulating M1 polarization, while simultaneously 
down-regulating arginase I (M2) and MMP-9 production as seen in THP-1s exposed to 
BCC supernatant with imiquimod as compared to BCC supernatant without imiquimod 
(Figure 10). The arrows on the histograms indicate the direction of skewing induced by 
imiquimod (Figure 10). A similar pattern is observed in another experiment with THP-1 
cells incubated in SCC-conditioned media in presence and absence of imiquimod (Figure 
10). In conclusion, imiquimod lead to significant M1 activation and down-regulation of 
M2 polarization and MMP-9 production in macrophages primed in tumor-conditioned 





Imiquimod-treated THP-1 cells induce apoptosis in human epidermoid carcinoma 
cells  
In order to determine whether imiquimod can activate anti-tumoral capacity of 
macrophages, we designed an experiment using THP-1 cells and A431 epidermoid 
carcinoma cells. THP-1 cells were first primed by imiquimod or control media for 48 
hours and then cells were washed. The resulting control and imiquimod-primed THP-1 
cells were then utilized in a co-culture system with epidermoid carcinoma cells. The 
tumor cells were plated and control and imiquimod pre-treated THP-1 cells were placed 
in the upper Transwell insert. After 72 hours of incubation, we measured level of 
apoptosis in epidermoid carcinoma cells using Annexin FITC kit (eBioscience) and 
propidium iodide. This experimental setup is a non-contact-dependent system that allows 
exchange of soluble factors from THP-1 cells to tumor cells. 
The level of apoptosis in tumor cells exposed to control THP-1 cells and 
imiquimod-primed THP-1 cells is shown in Figure 11. The graph shows propidium 
iodide-PerCP versus Annexin V- FITC staining (Figure 11). Early apoptosis was 
measured by determining the percentage of Annexin V-positive cells, which are negative 
for propidium iodide. The rate of early apoptosis was 12.2 % in the imiquimod group as 
compared to 8.47 % in control group (Figure 11). This demonstrates that imiquimod 
priming the THP-1 cells resulted in a higher level of early apoptosis of epidermoid 
carcinoma cells compared to naive THP-1 cells. Late apoptosis was measured as 
percentage of double positive cells for Annexin V-FITC and propidium Iodide-PerCP 




cultured with imiquimod primed macrophages as compared to 1.04 % in the tumor cells 
co-cultured with naive macrophages (Figure 11). These findings reveal a six-fold increase 
in the level of late apoptosis of tumor cells in the imiquimod-primed group as compared 
to the control group.  
THP-1 cells primed with imiquimod phagocytose significantly more tumor cells 
compared to naive THP-1 cells 
 To whether imiquimod induces macrophage phagocytosis of tumor cells, we 
devised a phagocytosis assay using PE-labeled tumor cells and human macrophages 
primed with imiquimod. First, THP-1 cells were incubated in media with and without 
imiquimod for 48 hours. The THP-1 cells were then washed and used for tumor cell 
phagocytosis experiments. A431 epidermoid carcinoma cells were labeled with PE dye 
using PKH26 kit (Sigma Aldrich). The cell membrane PE labeling allows the 
phagocytized cells to be quantified using flow cytometry. PE-labeled epidermoid 
carcinoma cell were mixed with control or imiquimod-primed THP-1 cells in a ratio of 
6:1 to mimic the in vivo tumor microenvironment. The samples were then incubated in a 
shaking TC incubator for 1 hour at 200 rpm. Samples were then prepared for flow 
cytometric analysis using CD45 APC.  
The level of phagocytosis was determined by measuring the percentage of PE-
positive, CD45+ macrophages (Figure 12).  Interestingly, the rate of phagocytosis was 
68.2 % in the imiquimod-primed macrophages as compared to 8.22 % in the control 
naive macrophages (Figure 12). The cell-free negative control had a background level of 
0.27 % positive staining as expected (Figure 12). These findings demonstrate that 







TAMs in cutaneous SCCs have higher levels of both M1 and M2 polarization than 
those TAMs in BCCs 
We hypothesized that TAMs from SCC had a different level of activation than 
those from BCCs given their markedly different clinical features.  To test this, we 
isolated tumor associated macrophages from SCCs and BCCs in vivo and characterized 
them with multiple panels utilizing florescent active cell sorting (FACS).  FACS 
experiments on cutaneous neoplasms have been historically challenging due to technical 
difficulty of digestion of such highly collagenous tumors while preserving cell viability. 
This study presents a technical advance in the field by providing a simple, reproducible 
technique for creating a viable cell suspension of SCCs and BCCs that is suitable for flow 
cytometric analysis of the wide variety of cell types that make up these skin tumors. The 
FACS immunophenotype panel of TAMs in cutaneous SCCs demonstrates that 
macrophages have a heterogeneous activation state characterized by both M1 and M2 
activation (Figure 2). Based on our flow cytometric immunophenotypes from multiple 
tumors (n=14), all from different patients, TAMs are consistently activated with profiles 
unique to SCCs versus BCCs, with SCCs demonstrating higher M1 and M2 activation 
(Figure 2).  Our findings are in agreement with recent findings of M1 and M2 gene 
expression profile of TAMs in SCC (24). The authors show that TAMs in SCC are 
heterogeneously activated, exhibiting both M1 and M2 states of activation, and that 
macrophages can simultaneously express genes commonly associated with Th1 and Th2 




tumors (n=3) and peri-tumoral normal skin samples (n=3) from the same patients. This 
served a control for TAMS as tissue resident macrophages can have varied phenotypic 
characteristics depending on their tissue niche. Dermal macrophages from the same 
patient are the ideal control for immunophenotype characterization of TAMs in vivo in 
human SCCs. The results demonstrate that TAMs in SCCs are M1 and M2 activated and 
also express high MMP-9 levels compared to skin-resident macrophages (Figure 5).  
The simple categorization of macrophages into M1 and M2 phenotypes does not 
capture the observed complexity of TAM activation in SCC microenvironment. 
Therefore, a revised model of macrophage activation states taking into account the shades 
and overlaps of activations states known as the color wheel of macrophage activation is 
more appropriate in explaining the in vivo behavior of macrophages (20, 32). In this 
model, macrophages are divided into three populations: classically activated 
macrophages, wound-healing macrophages, and immune regulatory ones, while allowing 
for overlap of these three states on a color wheel (20, 32). The phenotypic complexity of 
TAMs is possibly due to heterogeneity of the tumor microenvironment ranging from 
hypoxic and necrotic regions to more vascularized regions; In addition, infiltration by a 
variety of T cells, IFN-gamma producing Th1, IL-4 and IL-13 producing Th2 cells and 
IL-10 producing T-reg cells results in a heterogeneous cytokine milieu in the tumor 
microenvironment. In support of this hypothesis, it has been shown that SCC is 
associated with a mixed Th1 and Th2 gene expression profile (33). In addition, It is 
important to note that the monocyte lineage, the precursor to TAMs and tissue-resident 
macrophages, are themselves heterogeneous, yet providing another potential factor that 




SCC and BCC can produce cytokines such as IL-10 further contributing to the diverse 
nature of chemical messages in the tumor niche (35). 
 
Higher MMP-9 and arginase I Expression in TAMs in SCCs versus BCCs  
MMPs are a family of zinc-dependent neutral endopeptidases that can break down 
the components of the extracellular matrix (ECM) (36). MMPs play an active role in 
many aspects of tumor development including angiogenesis, local tissue invasion, and 
metastasis (37). The ECM is a net of connective tissue that stands in the way of tumor 
growth and invasion.  When tumor cells are embedded in this rigid, spheroid matrix, 
tumor proliferation is suspended (38). In addition to tumor proliferation, MMPs allow 
tumor cells to locally invade and metastasize through vascular and lymphatic pathways 
through breakdown of basement membrane proteins (39, 40). Macrophages are known to 
produce matrix metalloproteinase, primarily MMP-9 and MMP-2 and can contribute to 
tumor growth, invasion and metastasis by supplying this pivotal factor in the tumor 
microenvironment (22, 23).  
Increased expression of MMP-9 in TAMs from SCCs as compared with BCCs is 
an interesting finding that suggests a possible reason for the difference in clinical 
behavior between SCC and BCC (Figure 2). MMP-9 supplied by bone marrow-derived 
cells has been shown to be involved in skin carcinogenesis (41). A murine model of 
HPV16-induced de novo SCC demonstrated that MMP-9 knock out mice have reduced 
keratinocyte proliferation and delayed progression from hyperplasia to dysplasia and 
finally to invasive carcinoma (41). In a similar manner, immunohistochemical studies of 




increased expression of MMP-9 and MMP-2 and decreased collagen IV when compared 
to BCC (42). Given this essential role of MMP-9 in skin carcinogenesis, increased MMP-
9 produced by TAMs in SCC versus BCC can partly explain the clinical behavior of 
these two tumor types.  
Arginase I is a key enzyme that is involved in polyamine production (putrescine, 
spermine, spermidine). Arginase I converts Arginine to Ornithine, which is subsequently 
converted to putrescine by Ornithine Decarboxylase (ODC). Putrescine is then 
interconverted to other polyamines through the actions of spermidine synthase and 
spermine synthase (43). This biochemical pathway leads to production of polyamines in 
the tumor niche, which can then be utilized by tumor cells for cellular proliferation and 
growth (44). The distinctly higher levels of arginase I in TAMs from SCCs versus BCCs 
may be a pathophysiologic reason for the higher growth rates observed in SCC as 
compared to BCC (Figure 2). Finally, higher expression of arginase I in TAMs from 
SCCs also demonstrates that there are more M2, tumor-promoting macrophages present 
in SCCs as compared to BCCs.  
 
Soluble factors are sufficient to reproduce the TAM immunophenotype 
Co-culture of human cutaneous SCC with THP-1 cells demonstrated that cells in 
the tumor microenvironment are able to induce M1 and M2 polarization in macrophages 
in vitro through non-contact-dependent, paracrine communication (Figure 6). The fact 
that normal skin from the same patient does not induce the phenotype demonstrates that 
the soluble factor(s) are present in the tumor and absent from adjacent “normal” tissue. 




heterogeneous M1 and M2 activation and increased MMP-9 production as compared to 
peri-tumoral normal skin and BCC (Figure 2 and 5).  Increased MMP-9 production in 
THP-1 cells as a result of co-culture with SCCs is also consistent with our in vivo results 
of TAMs in SCCs.  
The possible mechanism of TAM immunophenotype induction is through soluble 
factor(s) that are responsible for induction of TAM immunophenotype (Figure 7). The 
source of such signaling factors can include tumor cells, Th1 and Th2 cells, other 
immune cells, fibroblasts, and variety of other cells in the tumor microenvironment. In 
support of this hypothesis, we demonstrated that THP-1 cells could be induced to their 
respective M1-M2 phenotype in vitro using filtered (cell-free) tumor-conditioned media 
from SCCs and BCCs (Figure 7). The results show a stepwise increase in mean florescent 
intensity from THP-1 cells incubated with control media to the BCC-conditioned media 
to the SCC-conditioned media (Figure 7). In summary, the results of both SCC and peri-
tumoral normal skin co-culture with THP-1 cells together with in vitro THP-1 cell 
polarization with SCC-conditioned and BCC-conditioned media further support the in 
vivo FACS immunophenotype of TAMs isolated from NMSC (Figure 2, 6, and 7). Given 
the heterogeneity and complexity of the tumor niche, monocytes recruited into the tumor 
microenvironment are exposed to a multitude of factors. Based on our findings, the 
heterogeneous, multi-focal activation is most likely the result of multiple soluble factors 
that act through a paracrine, non-contact-dependent relationship to induce an intricate 






Imiquimod induces M1 activation of TAMs in vivo and in vitro 
TAMs have been described as as a double-edged sword in cancer biology (45). It 
is important to understand their multifaceted behavior in order to devise ways to alter 
their activation state as a therapy for cancer. It is known that TAMs are dynamic and can 
be polarized into different activation states through exposure to different cytokines and 
immunomodulators (21, 23, 46). Given the broad role of TAMs in a variety of 
malignancies, it is conceivable that macrophage-targeted therapies will be useful for 
numerous cancers. Both imiquimod and resiquimod have been shown to be 
immunomodulators of T cells through the enhancement of Th1 cells and IFN-gamma 
production (47). Clinically, treatment of superficial BCC with 5 % imiquimod leads to 
significant increase in infiltrating CD68+ macrophages compared to baseline (48). 
Similarly, treatment of actinic keratoses (AK) with imiquimod leads to increase in gene 
expression of macrophage markers (CD163, CD14, CLECSF9) and activated T cells 
including cytotoxic T cells and Th1 cells (49). The increased infiltration of macrophages 
into BCCs and AKs after treatment with imiquimod has significant implications in terms 
of the mechanism of imiquimod's tumoricidal action. We analyzed published microarray 
data of up-regulated genes in BCCs (n=36) after topical imiquimod therapy. Ten known 
M1 genes are up-regulated through imiquimod treatment including CD40, CCR7, CD86, 
STAT1, MX-1, CXCL9, CXCL10, CCL2, CCL3, and CCL4 (Supplementary Figure 1) 
(50). 
We sought to determine the state of polarization of TAMs in vivo in response to 
imiquimod treatment using flow cytometric immunophenotyping of SCCs as compared to 




of TAMs as shown by increased levels of CD40 and CD127 as compared to control SCCs 
(Figure 9). Similarly, in vitro stimulation of THP-1 cells with imiquimod and resiquimod 
induced M1 activation as well (Figure 8). From a mechanistic viewpoint, M1 
macrophages are known to have potent tumoricidal properties mediated by production of 
pro-inflammatory factors (51). Given that Th1 cell are induced by imiquimod, one of the 
contributors to M1 polarization of macrophages by imiquimod is possibly through Th1 
production of IFN-gamma (21). Interestingly, using imiquimod alone, we showed that 
strong M1 activation could be reproduced with human monocytic cell lines in the absence 
of T cells and other cytokines (Figure 8). Therefore, imiquimod and resiquimod are 
sufficient to attenuate macrophage polarization without the need of adaptive immune 
cells.  Imiquimod is known to be a TLR-7/8 agonist and this maybe the mechanism of 
M1 polarization that we have observed in vivo and in vitro (52). 
 
Imiquimod is an immunomodulator of macrophages 
The results in Figure 10 provide insight into a novel mechanism of imiquimod’s 
action that we subsequently studied further using in vitro experiments to model the tumor 
microenvironment. We obtained tumor-conditioned media through manual dissociation 
of Mohs debulked tumors incubated in complete media for 24 hours and which we then 
filtered in a sterile fashion. Next, we polarized THP-1 cells in presence or absence of 
imiquimod to study effects on macrophage polarization. Imiquimod leads to strong M1 
polarization and simultaneous reduction in both M2 polarization and MMP-9 production 
(Figure 10). These findings imply that under conditions that model the microenvironment 




in a high M1 and low M2 polarized state. This modulated state of polarization is 
markedly distinct from the TAM immunophenotype that we have shown in vivo and in 
vitro and provides insight to a potential mechanism of imiquimod. The other implication 
is that TAMs in human tumors exhibit plasticity and can be modulated through both 
amplification of their tumoricidal effects and attenuation of their tumor-promoting 
functions. TAMs provide a continual supply of growth factors, angiogenic factors and 
MMPs that contribute to growth, invasion, and metastasis of tumor cells (3, 53). 
Macrophage immunomodulators may be useful across a variety of tumor types as TAMs 
are present in numerous types of tumors. 
 
Imiquimod-primed macrophages induce apoptosis of tumor cells and demonstrate 
enhanced phagocytosis of epidermoid carcinoma cells 
We asked question of whether imiquimod can induce macrophage to display 
tumoricidal activity. We specifically focused on apoptosis of tumor cells and 
phagocytosis of tumor cells by macrophages. In our apoptosis experiments, imiquimod-
primed macrophages induced apoptosis of epidermoid carcinoma cells at a level six-fold 
greater than naïve macrophages (Figure 11). This was carried out in a non-contact 
dependent co-culture system. The results demonstrate that imiquimod can induce 
macrophages to exhibit tumoricidal activity through the secretion of soluble cytotoxic 
factors that can cause both early and late apoptosis in carcinoma cells (Figure 11). Given 
that M1 macrophages are known for their pro-inflammatory activity against infectious 
agents, we speculate that imiquimod causes macrophages to polarize to an M1, pro-




necrosis factor (TNF), Nitric Oxide (NO), and reactive oxygen species leading to 
increased apoptosis of tumor cells (51). 
 We devised a phagocytosis assay utilizing PE-labeled epidermoid carcinoma cells 
and THP-1 macrophages primed with imiquimod to investigate whether imiquimod 
enhances the phagocytic activity of macrophages. In a contact system, tumor cells labeled 
with PE were incubated in suspension with control and imiquimod primed macrophages. 
Interestingly, imiquimod primed macrophages had significantly enhanced phagocytic 
activity. The rate of phagocytosis of PE-labeled tumor cells was 68.2 % in the imiquimod 
primed macrophage group compared to 8.22 % in the control macrophage group (Figure 
12). The results of these experiments demonstrate that imiquimod can activate 
tumoricidal activity of macrophages as shown by both enhanced apoptosis and 
phagocytosis of tumor cells by imiquimod-activated macrophages.  
In conclusion, using a novel method of FACS immunophenotyping of SCC and 
BCC tumor cells, we have shown that TAMs in human cutaneous SCCs show a 
heterogeneous M1 and M2 activation state. TAMs in SCCs express significantly higher 
levels of M1 (CD40, CD127) and M2 (arginase I) markers as compared to BCCs and also 
express higher levels of MMP-9, a pivotal factor in ECM remodeling and tumor invasion 
(36, 38, 39).  SCC, a relatively aggressive human skin cancer, is able to induce a more 
highly polarized TAM population, which is capable of both tumor-promoting functions 
(M2, MMP-9) and tumor-inhibiting functions (M1) in vivid contrast to the more indolent 
skin cancer, BCC. These findings demonstrate that TAMs may play an important role in 
pathophysiology of NMSC, the most common cancers in humans. Future studies include 




tumor microenvironment and also in the identification of soluble macrophage 
modulators.  
Further, we demonstrated that imiquimod, a TLR-7 agonist approved by the FDA 
for the treatment of superficial BCC, is able to induce M1 polarization in TAMs from 
human SCC and can induce the same phenotype in vitro. Further, imiquimod directly 
induces M1 polarization and suppresses M2 polarization in a tumor microenvironment 
assay. In functional assay, we demonstrated that activates macrophages to both induce 
apoptosis and phagocytosis of carcinoma cells.  
Taken together, these results suggest a mechanism by which imiquimod activates 
TAMs to an M1 polarized state capable of induction of apoptosis and phagocytosis of 
tumor cells.  These results reveal a novel immunologic mechanism for imiquimod in the 
treatment of skin cancer and suggest that modulation of TAM immunophenotype may be 






Table A - Characteristic of Subjects and tumor specimens 
 
 
Abbreviations: M- Male, F- Female, L- Left, R- Right, SCC- Squamous Cell Carcinoma, BCC- Basal Cell 




Type Age Gender Duration 
of lesion
Tumor size (cm) Location Skin CA history 
1 BCC 54 M 2 years 1.8 x 1.8 L to midline mid back none
2 SCC 58 M 6 months 1.2 x 1.2 L temple Infitrative BCC, SCC, BCCs
3 SCC 100 M 6 months 2.5 x 2.5 L radial hand BCC, SCC
4 SCC 98 F 3 months 2.0 x 2.5 L cheek SCC
5 BCC, Micronodular 71 M 2 years 0.4 x 0.5 L forehead none
6 SCC 95 F 3 months 2.0 x 1.8 R nasal bulb SCC
7 BCC 78 M 6 months 1.2 x 1.0 L inferior eyelid none
8 BCC 77 M 1 year 1.5 x 1.1 L side of nose BCC, SCCis, malignant melanoma
9 BCC, nodular and infiltrating 76 M 6 months 1.0 x 1.2 L zygoma BCC
10 SCC 49 M 6 months 0.8 x 0.9 L cheek SCCis, Aks, SCC, BCC
11 SCC, Invasive SCC to base 85 M 3 months 0.9 x 0.8 L ear none
12 SCC 81 M 6 months 1.0 x 1.2 R inferior cheek BCC
13 SCC 96 F 6 months 1.8 x 2.3 R medial cheek none
14 SCC 65 M 3 months 1.3 x 1.4 Frontal Scalp SCC, BCC
15 SCC 51 M 6 months 1.3 x 0.9, 1.0 x 1.5 L preauricular, L Scalp Invasive SCCs, Aks
16 BCC- to base 66 M 6 months 0.7 x 0.7 R nose none
17 SCC 78 M 1 month 1.3 x 1.3 L forehead none
18 SCC, Peri-tumoral skin 83 M 2 months 2.6 x 3.4 R cheek SCC
19 SCC 85 M 3 months 1.3 x 1.4 R distal shin AK, BCC
20 SCC 92 F 3 months 2.0 x 2.0 L mid anterior leg AK
21 BCC with infiltrative features 63 M 10 years 3.5 x 2.4 L chest none
22 SCC 83 F 3 months 0.8 x 0.8 L cheek none
23 BCC 87 F 5 years 3.0 x 3.0 Back none
24 SCC 91 F 1 year 1.0 x 1.0 R lower cheek SCCis, Atypical nevus
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Figure 1 Higher density of CD68+ tumor-associated macrophages are found in cutaneous SCC as 
compared to BCC 
 (a) BCCs (n=6) and SCCs (n=5) were stained with CD68 antibody, a marker of tumor-associated 
macrophages (TAMs) and visualized at 40X.  
 (b) Number of CD68+ TAMs was counted in six high power fields (HPF) for each BCC and SCC using 
Optiphot Nikon microscope with camera. Number of TAMs per HPF in SCC is significantly higher than 
BCC as shown in this graph (* p-value < 0.0001, unpaired t test) 
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Figure 2 Tumor-associated macrophages in SCC and BCC show differential activation based on flow 
cytometric immunophenotype of M1 and M2 markers 
 
(a) SCCs (n=7) and BCCs (n=7) excised using Mohs were enzymatically dissociated with Liberase for flow 
cytometric immunophenotyping. CD68-PE and CD45-APC were utilized as macrophage marker and 
common leukocyte marker respectively. As seen on this FACS plot, CD68+CD45+ population was gated 
upon as TAMs. CD68-CD45+ were gated upon to represent other white blood cells (other WBCs). The 
CD68-CD45- population seen in these plots represents tumor cells and other non-hematopoietic cell types 
in the tumor microenvironment.  
(b) Histograms of MMP-9 and arginase I were created for TAMs (CD68+CD45+), shown in black, and 
other WBCs (CD68+CD45-), shown in grey. The resulting overlayed histograms show that MMP-9 and 
arginase-I have higher levels in TAMs as compared to other WBCs.  
(c) CD68+CD45+ TAMs in SCC and BCC were gated upon. Histograms of arginase-I, MMP-9, CD40, and 
CD127 were created and overlayed for comparison of TAM immunophenotype in SCC (red) vs. BCC 
(blue). Characterization of M1, pro-inflammatory surface markers shows that TAMs in SCC have higher 
levels of CD40 and CD127 compared to BCC. Characterization of MMP-9 and Arginase-I, which are 
markers of tumor-promoting TAMs, shows that TAMs in SCC microenvironment have higher levels of both 
markers as shown by noticeable histogram shifts in these plots.  
(d) CD163+CD68+ TAMs in SCC have higher levels of M1 (CD40, CD127), arginase I, and MMP-9 as 














Figure 3 Microarray of Human SCC and BCC shows differential expression of CD68, MMP-9, and 
arginase-I 
 
Whole tumor microarrays of human SCCs (n=13) and BCCs (n=11) and normal skin (n=4) from published 
data were utilized to calculated microarray signal density for MMP9, CD68, and arginase-I. MMP-9 
expression is higher in SCC compared to BCC, which are both higher than normal skin. Similarly, CD68, a 
classic macrophage marker shows higher levels of expression in SCC compared to BCC and normal skin. 
Arginase I shows high expression in SCC, but no expression in BCC or normal skin. %  arginase I  positive 
is defined as percentage of all samples with significant p-values indicating that the gene expression is 
present in microarray profile of the tumor. SCC shows 36.36 % of arginase I positivity whereas BCC and 
normal skin demonstrate 0 % arginase I positivity.  
Abbreviations: Arg-I (arginase I) 
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Figure 4 Subpopulation analysis of SCC and BCC tumor-associated macrophages demonstrates 
heterogeneous states of macrophage polarization 
 
M1 vs. M2 graphs were created for CD68+CD45+ cells using CD127 (M1) vs. arginase-1 (M2) plots. In 
BCC, 78.7 % of TAMs have baseline level of activation (78.7 %), M1 only activation (7.07 %), M2 only 
activation (5.82 %), and M1-M2 activation (8.37 %). In contrast, in a small SCC, 7.85 % of TAMs have 
baseline activation (7.85 %), 42.8 % M1 only (42.8 %), M2 only (5.49 %), and M1-M2 activation (23.6 
%). In large SCC, majority of TAMs have M1-M2 activation (94.1 %) and a small percentage have 
baseline activation (4.02 %). The results suggest that TAMs in SCC have heterogeneous M1-M2 
immunophenotype compared to BCC. In BCC, majority of TAMs are quiescent whereas in SCC most 
TAMs have a heterogeneous state of polarization.  
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Figure 5 TAMs in cutaneous SCC are heterogeneously activated in comparison with peri-tumoral 
skin-resident macrophages 
 
SCCs (n=3) and peri-turmoal normal skin (n=3) were used to compare CD68+CD45+ immunophenotype of 
TAMs as compared to skin-resident tissue macrophages. SCC from Mohs and the peri-tumoral normal skin 
from the same patient were used in each experiment. Tumors and peri-tumoral skin were digested using 
Liberase and prepared for flow cytometry. CD68+CD45+ cells were gated upon and histograms of arginase-
I (M2), MMP-9, CD127 (M1), and CD40 (M1) were created for both SCC and peri-tumoral normal skin. 
The results shows that TAMs in SCC (red) have higher levels CD127, CD40, MMP9, and arginase I as 
compared to tissue-resident macrophages in peri-tumoral normal skin (grey).  
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Figure 6 Co-Culture of Human SCC with Human monocytes (THP-1) leads to TAM programming 
 characterized by M1 and M2 activation compared to peri-turmoal normal skin 
 
SCC and peri-tumoral normal skin from the same patient were obtained from Mohs surgery. Tumor and peri-
tumoral skin were manually minced and plated in RPMI complete in BD falcon culture insert with 1 µm PET 
membrane and transferred to six-well plate containing 1 million THP-1 cells in RPMI complete. After 72 hours, 
THP-1 cells were stained for FACS Immunophenotype (M1, M2, and MMP-9). CD68+ CD45+ cells were gated 
upon, and histograms representatives of arginase I, CD127, CD40 and MMP-9 are shown above. THP-1 cells co-
cultured with SCC tumor cells have higher levels of M1 markers (CD40, CD127), M2 markers (arginase I), and 
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Figure 7 Polarization of THP-1s with SCC (red) and BCC (blue) conditioned media demonstrates distinct 
degrees of M1 and M2 activation 
 
SCCs (n=3) and BCCs (n=3) tumors from MOHS were minced and placed in RPMI complete media in 37 ºC tissue 
culture incubator for 24 hours. The supernatants were then sterile-filtered. THP-1 cells were incubated in control 
RPMI, SCC-conditioned RPMI and BCC-conditioned RPMI. THP-1s were then analyzed using flow cytometry for 
CD40, CD127, arginase I, and MMP-9. THP-1 cells (red) incubated in presence of SCC-conditioned media have 
higher levels of M1 markers (CD40 and CD127), M2 marker (arginase I), and MMP-9 compared to THP-1 cells 
(blue) exposed to BCC-conditioned media. Control THP-1 cells are shown in grey and demonstrate baseline 
expression of these markers.  
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Figure 8  Imiquimod (50 ug/mL) and resiquimod (10 ug/mL)  induce M1 activation of macrophages in vitro 
 
THP-1 cells were plated and the following media were used for incubation: Control RPMI media (negative 
control), 50 µg/mL imiquimod in RPMI, 10 µg/mL resiquimod in RPMI, and 100 ng/mL lipopolysaccharide (LPS) 
and 20 ng/mL Interferon-gamma (positive control). After 48 hours, THP-1 cells were analyzed using flow 
cytometry for M1 markers (CD40 and CD127). CD68+CD45+ cells were gated upon and histograms of M1 
markers were produced. Imiquimod and resiquimod induce marked M1 activation of THP-1 cells in vitro as shown 
by histogram shifts compared to negative control. The positive control of LPS and Interferon-gamma shows M1 
activation as expected. 
Figure 9 Imiquimod treatment of SCC in vivo induces M1 activation of tumor-associated macrophages 
 
SCC from scalp of a patient treated with topical imiquimod (2.5 %) for 2 weeks was excised with Mohs and processed 
for flow cytometric immunophenotyping of TAMs.  A similar SCC was used as control. CD68+CD45+ TAMs were 
gated upon and histograms of M1, M2, and MMP-9 were generated. 94.5 % of TAMs in imiquimod-treated SCC have 
M1 activation (CD40+) compared to 45.8 % of TAMs in control SCC. There is down-regulation of MMP-9 and no 
changes in arginase-I in TAMs from imiquimod-treated SCC compared to TAMs from control SCC. 
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Figure 10 Imiquimod leads to immunomodulation  of macrophages towards M1 and away from M2 in the 
presence of SCC- and BCC-conditioned media 
 
Tumor-conditioned media from SCC and BCC was prepared through mechanical dissociation of tumors and 
incubation for 24 hours in RPMI complete. The media was then sterile-filtered with 0.45 µm filter. THP-1 cells 
were plated in BCC or SCC-conditioned medias in the presence of 50 µg/mL imiquimod or absence of imiquimod 
as the negative control. After 48 hours of incubation, THP-1 cells were prepared for flow cytometry of M1 and 
M2 markers, and MMP-9. In both THP-1 cells exposed to SCC-conditioned media and BCC-conditioned media, 
imiquimod leads to up-regulation of M1 markers (CD40 and CD127) and down-regulation of M2 marker 
(arginase I) and MMP-9. The arrows indicated the direction of immunomodulation in each graph. Therefore, 
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Figure 11 Imiquimod-treated THP-1 cells induce enhanced apoptosis of human epidermoid carcinoma 
cells in a co-culture system 
 
THP-1s were stimulated with 50 µg/mL imiquimod in RPMI complete and control RPMI complete for 48 
hours. The supernatant was then aspirated carefully and the THP-1 cells were washed twice in cold PBS.  
A431 epidermoid carcinoma cells were plated in a six-well plate. THP-1 cells were placed in the upper 
Transwell insert. After 3 days of incubation, the level of apoptosis in the A431 epidermoid carcinoma cells was 
quantified using Annexin FITC and propidium iodide. The rate of early apoptosis (Annexin V+ Propidium 
Iodide -) is 8.47 % in control group and 12.2 % in the imiquimod group. The rate of late apoptosis (Annexin V
+ Propidium Iodide +) is 1.04 % in the control group and 6.01 % in the imiquimod group. The results suggest 
that imiquimod can enhance tumoricidal capacity of macrophage in a non-contact-dependent system as shown 
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Figure 12 THP-1 cells primed with imiquimod phagocytose significantly more epidermoid 
carcinoma cells (A431) compared to control THP-1 cells 
 
THP-1 cells were stimulated with 50 µg/mL imiquimod or control media for 48 hours. At the end of 
incubation, the media was aspirated and cells were wash twice in cold PBS. A431 epidermoid 
carcinoma cells were labeled with PE dye using PKH26 (Sigma Aldrich). Next, the control and 
imiquimod-primed THP-1 cells were mixed with A431 carcinoma cells in a ratio of 6:1 in conical 
tubes. The samples were then placed in a shaking incubator at 37 ºC for 1 hour at 200 rotations per 
minute. The samples were prepared for FACS using CD45 APC. CD45+ Cells were then gated upon to 
distinguish THP-1 cells from tumor cells. The rate of phagocytosis was determined by gating on 
CD45+ PE+ cells, which indicate marcophages that have phagocytosed PE-labeled tumor cells. The PE 
histogram of THP-1 cells in imiquimod group (red) shows significant shift compared to control group. 
Only 0.27 % of CD45+ THP-1 cells are positive for PE in the negative control without any tumor cells 
added. The rate of phagocytosis is 68.2 % in imiquimod-primed THP-1 cells as compared to 8.22 % in 
control THP-1 cells. These results suggest that imiquimod can enhanced the phagocytic capacity of 
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Supplementary Figure 1- 10 known M1 genes are up-regulated by imiquimod treatment of 
 BCC in a placebo-controlled study 
